AstraZeneca Pharmaceutical Group is strengthening its pioneering position in medical innovation, contributing to the sustainable development of the medical and pharmaceutical industry in Vietnam.
 |
| National Lung Cancer Research Conference jointly organized by K Hospital and AstraZeneca in June 2024 |
Recently, in the World's Best Companies 2024 Ranking published by Time Magazine, AstraZeneca ranked 68th out of 1,000 businesses and held the 55th position in the category of transparency in sustainability - the highest ranking among pharmaceutical companies.
“This recognition is a testament to the commitment of our more than 90,000 employees to transform healthcare systems through science-based solutions,” AstraZeneca said after the list was announced.
In Vietnam, with a steadfast commitment to improving patient outcomes and enhancing access to healthcare, AstraZeneca has played a key role in driving the transformation of Vietnam's healthcare system over decades.
AstraZeneca’s recent breakthrough treatments were discussed at the National Lung Cancer Research Conference, co-organized by K Hospital and AstraZeneca in June 2024. The conference brought together leading Vietnamese and international medical experts to share experiences and insights on new advanced research practices published in international lung cancer conferences.
AstraZeneca is committed to driving innovation in healthcare in Vietnam through breakthrough solutions. By collaborating with the Government, healthcare organizations, medical professionals and investing in research and development, we are developing innovative treatments that address unmet patient needs. 
Mr. Atul Tandon, General Director of AstraZeneca Vietnam
Attending the Conference, Deputy Minister of Health Nguyen Thi Lien Huong emphasized the importance of clinical research in developing new treatments and improving treatment outcomes for patients.
Over the past time, with the strong and comprehensive cooperation between AstraZeneca and the Vietnamese Government, the Ministry of Health and health organizations, the Company has promoted the implementation of breakthrough initiatives to address important challenges in health care and bring many practical benefits to the Vietnamese people, such as the Program "For Healthy Lungs", "Adolescent Health", "CaReMe - Love Yourself", Medical Innovation Network and many other programs.
Specifically, launched in 2023, the Healthcare Innovation Network, co-organized by AstraZeneca and the Vietnam Young Physicians Association, to accelerate the application of digital tools in screening and detecting non-communicable diseases (NCDs), has been deployed in many provinces and cities across the country, such as Hanoi, Ho Chi Minh City, Da Nang, Can Tho, Thua Thien Hue, with more than 60 participating hospitals and screening lung diseases for more than 100,000 people.
By 2024, it is expected that more than 100,000 people nationwide will be examined for lung diseases, supported by X-rays and CT scans. People nationwide can screen for lung diseases and lung cancer by sending information and films.
X-ray to artificial intelligence (AI) platform operated by Vietnam Young Physicians Association, more than 1 million people are expected to be screened.
In parallel with investing in research and development, AstraZeneca also makes sustainable development one of its development focuses. Recognizing the link between human health and the health of the earth, AstraZeneca has made investment commitments towards environmental protection and sustainable development.
Also last year, within the framework of the AZ Forest Program being implemented in many countries around the world, AstraZeneca announced an investment of up to 50 million USD in Vietnam to restore Vietnam's forests and landscapes, thereby contributing to the country's Net Zero goals and the National Strategy on Climate Change for the period up to 2050.
In order to gradually create an ecosystem that helps patients effectively access quality care and treatment, AstraZeneca said it has been granted a certificate of registration by the Ministry of Science and Technology to transfer production technology and packaging processes to partners in Vietnam to produce some of AstraZeneca's advanced pharmaceuticals in Vietnam.
This is part of the AstraZeneca Group's $90 million investment to help Vietnam improve its domestic pharmaceutical production capacity. It is expected that in the 2022-2030 period, three important AstraZeneca generic drug products will have technology transferred for production in Vietnam.
Mr. Atul Tandon, General Director of AstraZeneca Vietnam shared: “AstraZeneca is always committed and strives to promote innovation in the field of healthcare in Vietnam through breakthrough solutions. By collaborating with the Government, healthcare organizations, medical professionals and investing in research and development, we are developing advanced treatments to address the unmet needs of patients. At the same time, AstraZeneca's focus on sustainability is the guiding principle to ensure that these advances will not only benefit patients in Vietnam, but also the community, society and our planet.”
Established in 1994, AstraZeneca Vietnam has invested US$360 million over the past decade, with a focus on reducing the burden of disease, improving patient access to healthcare, enhancing domestic biopharmaceutical research and development and manufacturing capacity, as well as developing local talent and sustainable development. The company has invested US$70 million in research and development to conduct clinical trials, thereby strengthening the country’s research capacity and improving early access to innovative medicines for patients.
With its contributions to the healthcare sector over the past 30 years of operation in Vietnam, AstraZeneca Vietnam has received many certificates of merit and awards from the Prime Minister, the Ministry of Health and domestic and foreign organizations. Most recently, the Company was awarded the Excellence Award for Science, Technology and Innovation by the British Chamber of Commerce (BriCham) and the Sustainable Development Enterprise Award by Nhip Cau Dau Tu Magazine.
In 2023, AstraZeneca invested USD 10.9 billion in research and development globally. The Group's commitment is demonstrated by consistently achieving high rankings in the global Pharmaceutical Innovation and Invention Index, specifically 1st in Patents and 3rd in Innovation in 2023.
AstraZeneca is supporting 68 clinical studies at nearly 50 hospitals across Vietnam, with more than 6,500 patients participating.
Source: https://baodautu.vn/astrazeneca-cung-co-cam-ket-doi-moi-sang-tao-d225732.html
![Charming Vietnam [ Cat Tien National Park ]](https://vstatic.vietnam.vn/vietnam/resource/IMAGE/2025/2/12/c05c34322e4f4cac874e7f971dfaddca)
Comment (0)